J&J’s Nipocalimab for FNAIT Gets on Fast Track for Approval

FDA granted fast track designation to nipocalimab, which J&J is developing for helping alloimmunized pregnant adults treat FNAIT, a rare disease that poses risk to the fetus or newborn.